• How Is The Intestinal Microbiome Altered in Patients With IBD and Does it Change During Therapy?

How Is The Intestinal Microbiome Altered in Patients With IBD and Does it Change During Therapy?

Treatment of inflammatory bowel diseases (IBD) with anti-tumor necrosis factor (anti-TNF) drugs restores diversity to the intestinal microbiome, researchers report in the November issue of Gastroenterology.  The study associates metabolic interactions among luminal bacteria with outcomes of therapy. Altered interactions between the mucosal immune system and intestinal microbiota contribute to

Read more
  • Can a Food-based Diet Replace Exclusive Enteral Nutrition for Patients With Crohn’s Disease?

Can a Food-based Diet Replace Exclusive Enteral Nutrition for Patients With Crohn’s Disease?

An individualized, food-based diet with similar composition of nutrients to exclusive enteral nutrition (EEN), causes similar changes in the microbiomes of patients with Crohn’s disease (CD), reduces gut inflammation, and is preferred by patients, researchers report in the April issue of Gastroenterology. Non-medical treatments are needed for patients with CD. Diet

Read more
  • IBD Research Highlights from 2019 ECCO Congress

IBD Research Highlights from 2019 ECCO Congress

A variety of exciting findings from inflammatory bowel disease (IBD) research were presented at the Congress of the European Crohn’s and Colitis Organisation (ECCO), held in Copenhagen, March 7–9. Shixian Hu (Universitair Medisch Centrum Groningen, The Netherlands) reported on associations between genetic factors and the microbiome in patients with IBD.

Read more
  • What is the Best Treatment Option for Fistulizing Crohn’s Disease?

What is the Best Treatment Option for Fistulizing Crohn’s Disease?

Tumor necrosis factor (TNF) antagonists are effective for induction and maintenance of perianal fistula response and remission in patients with Crohn’s disease (CD), a systematic review and meta-analysis shows in the December issue of Clinical Gastoenterology and Hepatology. However, there are few data on the effects on internal fistulae, and further studies

Read more
  • Decreased Microvilli Length, and Associated Gene Expression Changes, in Patients With Crohn’s Disease

Decreased Microvilli Length, and Associated Gene Expression Changes, in Patients With Crohn’s Disease

In an analysis of intestinal tissues from patients with Crohn’s disease (CD), researchers identified specific changes in gene expression patterns that associate with histologic changes, such as differences in microvilli length. Decreased microvilli length, via decreased expression of the microvilli gene set, might contribute to epithelial malfunction and the chronic

Read more
  • Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • 500 Posts by the AGA Journals Blog

500 Posts by the AGA Journals Blog

This week the AGA Journals Blog has reached an important milestone — its 500th post! The blog was started in 2010 to help disseminate the important discoveries published in the AGA Journals to a broader audience. Eight years and over 132,000 views later, it has updated its readers on everything from biomarkers for colon

Read more
  • Does Mucosal Healing Mean Transmural Healing in Children With Crohn’s Disease?

Does Mucosal Healing Mean Transmural Healing in Children With Crohn’s Disease?

 One-third of children with Crohn’s disease have healing in only the mucosa or the bowel wall (not both), researchers report in the July issue of Clinical Gastroenterology and Hepatology. Levels of fecal calprotectin below 300 μg/identify children with mucosal healing. In patients with CD, mucosal healing is associated with reduced risk of relapse,

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more
  • What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

When patients with Crohn’s disease in sustained remission stopped taking infliximab for a median 7 years, almost one fifth did not require retreatment or have a major complication, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Fewer than one fifth of patients required surgery or developed a complex perianal fistula. Increasing numbers of patients

Read more